

1 **Potential immunomodulatory role of VIP in the implantation sites**  
2 **of prediabetic NOD mice**

3

4 **Valeria Roca**<sup>1</sup>, **Mario Calafat**<sup>1</sup>, **Luciana Larocca**<sup>1</sup>, **Rosanna Ramhorst**<sup>1</sup>,  
5 **Mariana Farina**<sup>2</sup>, **Ana Maria Franchi**<sup>2</sup> and **Claudia Pérez Leirós**<sup>1\*</sup>

6

7 <sup>1</sup> Immunopharmacology Laboratory, Department of Biological Chemistry, School of  
8 Exact and Biological Sciences and <sup>2</sup> Laboratory of Physiopathology of Pregnancy and  
9 Labor, Center for Pharmacological and Botanical Studies (CEFYBO), School of  
10 Medicine, University of Buenos Aires, CONICET

11

12 **\*Corresponding author:**

13 Claudia Pérez Leirós, PhD, Professor

14 Ciudad Universitaria, Pab. II, 4<sup>th</sup> floor

15 1428 Buenos Aires, Argentina

16 Tel/fax: 5411-4576-3342 Email: cpleiros@qb.fcen.uba.ar

17

18

19 **Running title:** VIP and embryonic resorption in NOD mice

20 **Abstract**

21 Among several factors known to modulate embryo implantation and survival,  
22 uterine quiescence and neovascularization, maternal immunotolerance through the  
23 Th1/Th2 cytokine balance towards a Th2 profile, local regulatory T cell activation and  
24 high levels of progesterone were assigned a prominent role.

25 Vasoactive intestinal peptide (VIP) is a neuroimmunopeptide that has anti-  
26 inflammatory effects, promotes Th2 cytokines and CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T  
27 cell activation whereas it stimulates exocrine secretion, smooth muscle relaxation  
28 and vasodilatation favoring uterus quiescence. The goal of the present work was to  
29 explore the participation of VIP in the implantation sites of normal and pregnant  
30 prediabetic NOD females, a mouse strain that spontaneously develops an  
31 autoimmune exocrinopathy similar to Sjögren's syndrome. Our results indicate a  
32 reduction in litter size from the 3<sup>rd</sup> parturition onwards in the NOD female lifespan  
33 with increased resorption rates. Progesterone systemic levels were significantly  
34 decreased in pregnant NOD mice compared with BALB/c mice, although the  
35 allogeneic response to progesterone by spleen cells was not impaired. VIP receptors  
36 VPAC 1 and VPAC 2 were expressed at the implantation sites and VIP induced LIF  
37 and Treg marker expression in both strains, however, a reduced VIP expression was  
38 found in NOD implantation sites.

39 We conclude that the reduced birth rate at 16 week-old NOD mice with a Th1  
40 systemic cytokine profile involves resorption processes with a lower expression of  
41 VIP at the sites of implantation which acts as a local inducer of pro-implantatory LIF  
42 and regulatory T cell activation.

43

## 44 Introduction

45 During pregnancy, immune and neuroendocrine regulation of the maternal-  
46 fetal “dialogue” is central to both implantation and the development of the placenta.  
47 Several factors modulate embryo implantation and survival thus promoting maternal  
48 immunotolerance, uterine quiescence and neovascularization.

49 The Th1/Th2 cytokine shift towards a Th2 profile was shown as a favoring  
50 factor for fetus survival (Raghupathy 1997; Piccinni *et al.* 1998; Hanzlikova *et al.*  
51 2009). In line with this, patients with Th1 autoimmune diseases such as multiple  
52 sclerosis and rheumatoid arthritis improve during pregnancy (Nelson & Ostensen  
53 1997; Cutolo 2000; Olsen & Kovacs 2002). Also, reports showed that the incidence  
54 of fetal loss is not increased in autoimmune patients with rheumatoid arthritis while a  
55 significantly higher frequency of spontaneous abortion was found before the disease  
56 onset in a retrospective study of patients with Sjögren’s Syndrome (Siamopoulou-  
57 Mavridou *et al.* 1988). However, recent reports show that rather than a global Th2  
58 bias, most cytokine production appears regulated in the feto-maternal interface  
59 during early pregnancy to maintain a relative balance (Halonen *et al.* 2009).

60 Among various immunomodulatory factors that participate in the  
61 establishment and progression of gestation, progesterone has a prominent role by  
62 shifting Th1/Th2 cytokines to a Th2 profile (Szekeres-Bartho 2002). Also, high levels  
63 of progesterone prolong the survival of allogeneic skin grafts in hamster uteri  
64 (Moriyama & Sugawa 1972) while stimulation by fetal antigens induces the  
65 expression of progesterone receptors (Chiu *et al.* 1996). Allorecognition of paternal  
66 antigens can also increase the production of growth factors and hormones essential  
67 for embryonic and fetal development as leukaemia inhibitory factor (LIF) among  
68 others (Rugeles & Shearer 2004). Similarly, CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells (Treg) are  
69 known to have an essential role in the induction of maternal tolerance preventing  
70 spontaneous abortion (Aluvihare *et al.* 2004; Saito *et al.* 2007). A decreased number  
71 of decidual Treg cells were reported in the mouse model of abortion CBA/J x DBA/2

72 (Zenclussen *et al.* 2005) whereas CD4<sup>+</sup>CD25<sup>+</sup> T cell increase was stated from days  
73 2-3 of gestation independently of the allogeneic or syngeneic nature of pregnancy  
74 (Aluvihare *et al.* 2004). Also, CTLA4Ig gene transfer was recently shown to improve  
75 pregnancy outcome by expanding the CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cell population (Li *et al.*  
76 2009). Finally, LIF has also been involved in graft acceptance and alloantigen  
77 driven tolerance, whereas Tregs release high levels of LIF (Metcalfe *et al.* 2005;  
78 Zenclussen *et al.* 2006).

79 Vasoactive intestinal peptide (VIP) mediates a wide variety of nervous,  
80 immune and developmental functions. As a neuropeptide of the peripheral nervous  
81 system it stimulates exocrine secretion and vasodilatation (Ekström *et al.* 1983; Inoue  
82 *et al.* 1985). Interestingly, VIP contributes to smooth muscle relaxation and  
83 vasodilatation favoring uterus quiescence (Clark *et al.* 1981; Jovanovic *et al.* 1998).  
84 As an immunopeptide, it promotes anti-inflammatory and Th2 cytokine responses in  
85 various models of inflammatory response and autoimmune disease (Leceta *et al.*  
86 2007; Gonzalez Rey & Delgado 2007). VIP has been also proposed as an inducer of  
87 CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells (Tregs), helping to maintain immunotolerance  
88 in different animal models including NOD mice (Rosignoli *et al.* 2006; Gonzalez Rey  
89 & Delgado 2007). Finally, VIP participates in the maternal regulation of embryonic  
90 growth in rodents during the early postimplantation period and the blockade of VIP  
91 function induced growth retardation and microcephaly (Gressens *et al.* 1994; Spong  
92 *et al.* 1999, Rangon *et al.* 2006).

93 The non obese diabetic (NOD) mouse model of Sjögren's syndrome is an  
94 invaluable tool to study the outcome of pregnancy before the onset and during the  
95 autoimmune response. NOD mice at the prediabetic stage spontaneously develop an  
96 autoimmune exocrinopathy with a systemic Th1 cytokine response resembling  
97 Sjögren's syndrome. A deep exocrine dysfunction precedes a mild mononuclear  
98 infiltration of the glands which can be partly explained by multiple immune regulatory  
99 defects (Rosignoli *et al.* 2005; Anderson & Bluestone 2005; Piccirillo *et al.* 2005).

100 Among these defects, NOD mice present a lower number of Tregs, although they  
101 retain their suppressive capacity since depletion accelerates the progression of the  
102 autoimmune response (Pop *et al.* 2005). Regarding reproductive tissues, we have  
103 previously reported a decreased response to VIP in the uterus of normally cycling 16  
104 weeks old prediabetic NOD mice, simultaneously to the increase of Th1 cytokines in  
105 serum (Roca *et al.* 2006).

106 The goal of the present work was to monitor the reproductive score of  
107 prediabetic NOD females focusing on the potential regulation by VIP of local  
108 modulatory factors at the implantation sites. We provide evidence of a reduced birth  
109 rate from the 3rd litter onwards at 16 weeks of age that is associated with increased  
110 resorption processes, decreased serum progesterone and decreased expression of  
111 VIP at the sites of implantation, which acts locally as an inducer of pro-implantatory  
112 factors LIF and Treg activated cells.

113

## 114 **Results**

### 115 **Litter size in NOD mice lifespan and embryonic resorption profile**

116 Figure 1A shows a significant decline in the litter size of NOD mice from the 3<sup>rd</sup>  
117 parturition onwards. It is worth noting that the first reduction in litter size is around the  
118 18<sup>th</sup> week of mothers' age. These females had been mated at 16 weeks of age  
119 coinciding with the onset of the systemic Th1 cytokine response previously described  
120 in these mice (Roca *et al.* 2006). A more profound failure in reproductive score is  
121 registered at the diabetic stage that occurs about the 30<sup>th</sup> week in our breeding  
122 conditions. Control BALB/c mice litter sizes (Figure 1B) show that there is no decline  
123 up to the 4<sup>th</sup> gestation and even not further (28 weeks of age, data not shown). To  
124 investigate whether this decline in offspring at the 3<sup>rd</sup> gestation was an effect of  
125 multiple gestations or it also occurred at the first pregnancy, we mated virgin NOD  
126 females of 16 weeks of age and obtained similar results (NOD mice born/mother,  
127 mean  $\pm$  S.E.M. = 5,0  $\pm$  0,8). Also, since diabetes is known to impair pregnancy in this

128 strain, we measured glucose serum levels in pregnant 16 weeks old NOD mice,  
129 either in their first gestation or in the third one. Glucose levels did not differ either  
130 between NOD mice or compared to normal BALB/c pregnant mice (Table 1). In order  
131 to explore whether an implantation failure or a resorption process underlies this lower  
132 offspring score, we mated 16 weeks old female NOD mice (first mating) with male  
133 NOD mice. On the 9<sup>th</sup> day after the vaginal plug was seen, female mice were  
134 sacrificed, post implantation embryos were counted and separated for histological  
135 studies. As it can be seen in Figure 2A, healthy embryos were macroscopically  
136 different from those in process of resorption. Histological studies revealed a  
137 conserved muscular layer, infiltrating immune cells in the decidualized tissue (a) and  
138 hemorrhages (b). In the lower panel, an incipient infiltration of aligned mononuclear  
139 cells can be seen as well as decidual cells detaching from the villi (c). The rate of  
140 resorbed embryos vs. total embryos was 32% (60 resorbed/187 evaluated) (Figure  
141 2B), higher than the normal rate reported for control mouse strains (Zenclussen *et al.*  
142 2006). Similar resorption rates were obtained in mothers NOD at 3<sup>rd</sup> gestation (not  
143 shown).

144

#### 145 **Serum levels of progesterone and estradiol and systemic alloreactivity**

146 Since progesterone and estradiol play key roles in the physiology of reproduction, we  
147 measured their levels in the serum of pregnant NOD and BALB/c mice. Compared  
148 with BALB/c mice, significantly lower progesterone levels were found in pregnant  
149 NOD mice serum even if they had no signs of embryo resorption (Figure 3A). In fact,  
150 progesterone levels were even lower in NOD mice with more than 4 resorption sites.  
151 However, no differences were seen in the estradiol levels in pregnant NOD mice  
152 compared to NOD mice with more than 4 resorption sites or with BALB/c mice  
153 (Figure 3A, left pannel). On the hypothesis that an exacerbated splenocyte  
154 alloresponse not properly regulated by progesterone might have a role in the  
155 increased resorption rate, we measured the maternal immune response to paternal

156 antigens by splenocytes in pregnant NOD and BALB/c mice at day 9 of gestation.  
157 When taking into consideration the proliferation rate, no significant difference was  
158 found between the two strains. Also, progesterone was able to inhibit the response to  
159 the same extent in both mice strains, suggesting that although progesterone levels  
160 are diminished in NOD mice, spleen cells present a similar response to paternal  
161 antigens and progesterone regulation compared with normal mice cells (Figure 3B).

162

### 163 **VIP and VPAC receptors expression**

164 VIP has smooth muscle relaxation effects and induces proTh2-proTreg profiles  
165 consistent with the maintenance of uterine quiescence and immuno-tolerogenic  
166 mechanisms, on one hand, and it has been also involved in fetal growth, on the  
167 other. Thus, we investigated the expression levels of VIP and VPAC receptors VPAC  
168 1 and VPAC 2 mRNA in NOD and BALB/c implantation sites. As shown in figure 4A,  
169 there was a decrease in VIP mRNA levels at the implantation sites of NOD mice  
170 compared with BALB/c mice. NOD mice with more than 4 resorption sites were also  
171 tested for VIP expression and the levels were significantly reduced compared to NOD  
172 mice with normal embryos. To quantify VIP mRNA expression, real time RT-PCR  
173 was performed and the above results were further confirmed (Figure 4B). In contrast,  
174 there were no detectable differences in mRNA levels of VPAC 1 or VPAC 2 receptors  
175 between normal NOD and BALB/c implantation sites (Figure 4C).

176

### 177 **Effect of VIP on pro-implantatory factors.**

178 Since VIP has been associated with induction of Tregs and we have described a  
179 lower response to VIP in uteri of non pregnant female NOD mice, we investigated the  
180 functionality of VIP receptors by exploring the ability of exogenous VIP to induce LIF  
181 expression and Foxp3 major differentiation marker of CD4+CD25+ Treg in the  
182 implantation sites. Hence, explants of healthy implantation sites from NOD and  
183 BALB/c mice were cultured for 24 h in the presence or absence of 100 nM VIP, and

184 the expression of Foxp3 and LIF was assessed by western blot. We observed that  
185 VIP significantly increased Foxp3 and LIF expression in implantation sites from NOD  
186 and BALB/c mice (Figure 5A). To further analyze the effect of VIP on Treg population  
187 we performed triple staining protocols to identify Treg population (CD4-FITC, CD25-  
188 APC, Foxp3-PE) in NOD and BALB/c mice healthy implantation sites. Figure 5B  
189 shows a representative dot plot for NOD and BALB/c mice in basal and VIP  
190 stimulated conditions. No detectable differences in the frequency of Tregs in basal  
191 conditions were seen between NOD and BALB/c mice, and also, VIP slightly  
192 increased the frequency of this population to the same extent in both mice strains.

193

194 **Discussion**

195 Pregnancy is a tightly regulated process where systemic and local mechanisms act in  
196 synchronicity to allow the maternal immune system to tolerate the fetus. A unique  
197 situation takes place when autoimmunity underlies the course of pregnancy.  
198 Certainly, the outcome of pregnancy may be affected by the autoimmune context and  
199 while pregnancy was shown to ameliorate various autoimmune diseases, it can also  
200 worsen the outcome of others (Waldorf & Nelson 2008). Therefore, a more deep  
201 insight into the mechanisms of maternal-fetal interaction in normal and autoimmune  
202 conditions might help to improve the current/available treatments. Several reports  
203 describe the effect of established autoimmune disease on pregnancy and its effect  
204 on disease, nevertheless, few retrospective reports focused on the outcome of  
205 pregnancy before the clinical manifestations of an autoimmune disease. This  
206 situation was analyzed in Sjögren's disease, more frequently diagnosed in elder  
207 women, and a higher frequency of recurrent spontaneous abortions was reported  
208 (Siamopoulou-Mavridou *et al.* 1988).

209 The aim of the present work was to analyze the reproductive score of  
210 prediabetic NOD females as a model of Sjögren's syndrome focusing on the potential  
211 role of VIP as a local immunomodulatory factor at the implantation sites. Our results  
212 indicate a decline of birth rate in NOD mice paralleling the development of the  
213 systemic Th1 cytokine response, with increased resorption rates, decreased  
214 systemic progesterone and decreased expression of VIP at the sites of implantation.  
215 VIP appears to act locally as an inducer of pro-implantatory factors LIF and Treg  
216 activated cells. These conclusions are supported by the following evidences  
217 presented: First, a reduction in litter size was recorded from the 3<sup>rd</sup> parturition  
218 onwards only in NOD mice. This occurred at an age of the mother when Th1  
219 cytokines such as TNF- $\alpha$  are increasing in their serum. Second, progesterone  
220 systemic levels are significantly decreased in pregnant NOD mice compared with  
221 BALB/c mice, although the response to progesterone by spleen cells is not impaired.

222 Third, a significant reduction in VIP mRNA levels was found locally in NOD  
223 implantation sites with normal expression of VIP receptors, VPAC 1 and VPAC 2.  
224 These receptors are responsive to exogenous VIP as it was able to increase the  
225 expression of two pro-implantatory markers, Foxp3 and LIF, in healthy implantation  
226 sites and to increase the frequency of Treg population.

227 The decrease in offspring around the 16<sup>th</sup> -18<sup>th</sup> week of age parallels not only the  
228 onset of the systemic Th1 cytokine response (Roca *et al.* 2006) but also the decline  
229 in salivary flow rate characteristic of Sjögren's syndrome-like stage in NOD mice and  
230 it also clearly precedes the hyperglycemia of the type 1 diabetic stage in NOD mice.  
231 (Rosignoli *et al.* 2005), since 16 weeks old pregnant NOD mice are normoglycemic.

232 In addition, we found that the resorption rate in this singeneic pregnancy model was  
233 significantly higher than the 3-10% resorption rate reported for allogeneic and  
234 singeneic pregnancy in control mouse strains. NOD resorption rates shown here are  
235 similar to allogeneic pregnancy in NOD/C57BL/6 of comparable age (Formby *et al.*  
236 1987; Lin *et al.* 2008) and comparable with the resorption rates reported for the  
237 immunologic abortive model CBA/2 x DBA/J (Zenclussen *et al.* 2006).

238 Embryonic resorption has been associated with systemic responses such as a Th1  
239 cytokine profile (Chaouat *et al.* 1990) and low progesterone levels (Elson & Jurkovic  
240 2004). At the local level, unusually high levels of nitric oxide synthesis are  
241 responsible of resorption in an acute inflammation model in mice (Ogando *et al.*  
242 2003; Aisemberg *et al.* 2007). Similarly, a low number of Tregs at implantation sites  
243 parallels resorption in the abortive mouse model (Aluvihare *et al.* 2004; Zenclussen  
244 *et al.* 2006). As we showed here, progesterone levels were decreased in the sera of  
245 pregnant NOD mice, and this reduction was even greater when resorbed embryos  
246 were counted at day 9 of gestation. Progesterone plays a key role in the regulation of  
247 gestation due to endocrine as well as immunological effects. Progesterone was found  
248 necessary for NK cells homing to the uterus mediating angiogenesis and  
249 neovascularization in human pregnancy (Ancelin *et al.* 2002). In line with this, we can

250 speculate that a reduction in progesterone serum levels could in turn impair NK cells  
251 homing to the uterus. Interestingly, a lower uterine NK cell number was observed in  
252 the decidua basalis of diabetic NOD mice females, along with reduced expression of  
253 vascular cell adhesion molecule (VCAM)-1 and aberrant expression of cell adhesion  
254 molecule (MAdCAM)-1 in deciduas (Burke *et al.* 2007). In the pregnant NOD mouse  
255 model of Sjögren's syndrome, we have recently shown that macrophages from  
256 mothers at 16 weeks of age and at day 9 of gestation present a lower basal  
257 production of IL-12 and nitric oxide than macrophages of age matched-non pregnant  
258 NOD mice (Larocca *et al.* 2008). Moreover, this 'silenced' condition of pregnant NOD  
259 macrophages could be partly mimicked in non pregnant NOD macrophages by  
260 incubating cells with progesterone. This result suggests that progesterone or  
261 progesterone/estradiol ratio, among other hormonal changes during gestation, is  
262 responsible for the anti-inflammatory macrophage profile. Interestingly, no significant  
263 differences were seen in estradiol serum levels in pregnant NOD mice, either with or  
264 without signs of resorption. Thus, in addition to the reduced progesterone levels, the  
265 relative ratio progesterone/estradiol is also decreased. Regarding Sjögren's  
266 syndrome patients, no significant differences were observed in the levels of  
267 estrogens and progesterone in sera between patients and controls although a higher  
268 estrogen/ progesterone relative ratio was reported (Taiym *et al.* 2004). It is worth  
269 noting that not only the appropriate levels of circulating hormones can influence the  
270 progression of gestation, but also the expression and signaling through their  
271 receptors. To further analyze this, we explored the allogeneic response of maternal  
272 splenocytes to paternal antigens and the inhibitory effect of progesterone. Though  
273 progesterone levels were reduced in pregnant NOD mice, the allogeneic response  
274 was similar in NOD and control mice. Moreover, progesterone added to the cultures  
275 inhibited the response to the same extent in both cultures confirming that  
276 progesterone receptors and signaling seem appropriate.

277 Regarding locally acting homeostatic signals, we have previously reported a reduced  
278 nitric oxide and increased prostaglandin E<sub>2</sub> synthesis in the uterus of NOD mice with  
279 a concomitant development of a Th1 cytokine profile (Roca *et al.* 2006). Both signals  
280 are known to impair the progression of gestation. Also, other authors have reported  
281 on aberrant endometrial features in diabetic pregnant NOD mice, where vascular  
282 defects (limited spiral artery development) due to a decreased NK cells activity,  
283 resulted in increased murine fetal loss (Burke *et al.* 2007).

284 On the knowledge that VIP has anti-inflammatory effects and promotes Th2/Treg  
285 profiles in several models of Th1 disease, while it showed an embryotrophic effect at  
286 days 9 to 12 of gestation in rodents, we investigated the presence of VIP in the  
287 implantation sites. Local expression of VIP mRNA was assessed at the implantation  
288 sites of NOD mice although at lower levels compared with control mice. VIP  
289 receptors VPAC 1 and VPAC 2 were also expressed at the maternal-embryonic  
290 interface suggesting that VIP could specifically act by a local/paracrine mechanism.  
291 The level of receptor expression was similar for both subtypes and for control and  
292 NOD healthy sites. Also, functionality of VIP receptors locally expressed was  
293 assessed by the addition of exogenous VIP to the media culture which induced a  
294 significant increase of Foxp3 and LIF expression and a trend to increase Tregs  
295 frequency. In rodent models of embryo implantation and growth, VIP levels increase  
296 in the deciduas at the early phases post-implantation and it has been assigned a role  
297 as a neural growth factor for the embryos (Gressens *et al.* 1998; Spong *et al.* 1999).  
298 Moreover, a reduction in the levels of VIP could lead to growth retardation and  
299 microcephaly (Gressens *et al.* 1994). We have recently reported on the expression of  
300 VIP and VPAC 1 receptor in a human trophoblast cell line (Fraccaroli *et al.* 2009). By  
301 means of an experimental approach to the human fetal-maternal interface, we  
302 showed the participation of endogenous VIP in the fetal-maternal interaction with a  
303 pro-implantatory role by increasing the expression of Treg markers and LIF  
304 (Fraccaroli *et al.* 2009). Other authors have reported on the ability of VIP to modulate

305 hCG and progesterone in human trophoblast cultures (Marzioni *et al.* 2005) and to be  
306 selectively concentrated in the uterine vasculature, where its levels have been  
307 reported to be 2.5 fold greater than in maternal blood (Ottensen *et al.* 1982).

308 Finally, VIP has been recently proposed as an inducer of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>  
309 regulatory T cells in vivo in the prediabetic NOD mice model (Rosignoli *et al.* 2006).

310 During pregnancy, a systemic expansion of CD25<sup>+</sup> Tregs has been shown and the  
311 lack of this subset leads to gestation failure (Aluvihare *et al.* 2004; Zenclussen *et al.*  
312 2006; Saito *et al.* 2007). A lower level of systemic Tregs was reported in diabetic  
313 NOD mice (Pop *et al.* 2005), however a role for these cells in NOD pregnancy has  
314 not been clarified yet.

315 The reduced expression of VIP at the sites of implantation of NOD mice confirm and  
316 extend the observations on the potential pro-implantatory role of VIP in the human  
317 maternal fetal dialogue recently reported by means of an *in vitro* approach (Fraccaroli  
318 *et al.* 2009). Further studies are needed to address the mechanisms underlying the  
319 potential role of VIP as a modulatory factor and the perspectives for its application to  
320 therapy of pregnancy failures.

321

322

323

## 324 **Materials and Methods**

325 *Animals:* NOD and BALB/c female and C57Bl6J males were bred and maintained at  
326 the Central Animal Care facility of the School of Exact and Natural Sciences,  
327 University of Buenos Aires. They were maintained on a 12:12 h light–dark schedule.  
328 Each mouse was considered mature at the age of 9-10 weeks. Normally cycling NOD  
329 and BALB/c mice were mated and day 0 was taken as the day when the vaginal plug  
330 was seen. Mice were fasted overnight with water *ad libitum* before sacrificed and  
331 tissues and blood were obtained and processed immediately after. Mice were  
332 routinely tested for blood glucose levels (Wiener Lab., Rosario, Argentina) and  
333 considered pre-diabetic as their values of serum glucose on two occasions over a 24-  
334 hour period did not significantly differ from those of control mice ( $1.0 \pm 0.1$  g/l, n=27).  
335 In our breeding conditions, NOD mice diabetes onset is around the 30<sup>th</sup> week of age  
336 and none of the pregnant animals used throughout were diabetic. Also, confirming  
337 previous reports (Roca *et al.* 2006), NOD mice sera were also assayed for TNF- $\alpha$   
338 levels showing a significant increase of this cytokine at 16 week-old NOD mice  
339 before mating compared with age-matched control mice (TNF- $\alpha$  pg/ml, NOD  
340  $230 \pm 11^*$ , BALB/c  $100 \pm 5$ ; \*  $P < 0.05$  vs BALB/c, n=7). All studies were conducted  
341 according to standard protocols of the Animal Care and Use Committee of the School  
342 of Exact and Natural Sciences, University of Buenos Aires.

343

### 344 *Immunohistochemistry*

345 Uteri from NOD and BALB/c mice were fixed in 4% paraformaldehyde overnight at  
346 4°C. The tissues were embedded in paraffin wax and sections of 4  $\mu$ m were cut and  
347 placed on silanized glass slides. Haematoxylin-eosin staining was performed as  
348 described elsewhere (Roca *et al.* 2004).

349

### 350 *Progesterone determination*

351 Progesterone was quantified by specific radioimmunoassay using rabbit antiserum  
352 (Sigma Chemical Co., St. Louis, MO, USA). Briefly, progesterone was extracted from  
353 sera with ethyl ether and repeated freeze/thaw cycles. (Abraham *et al.* 1971) The  
354 organic phase was dried in vacuum, resuspended in radioimmunoassay buffer and  
355 measured immediately. Tests were conducted in duplicate and results were  
356 expressed as mean  $\pm$  S.E.M (ng/ml).

357

#### 358 *Estradiol determination*

359 Estradiol was quantified by specific radioimmunoassay Coat a Count Estradiol  
360 (Siemens, Los Angeles, USA) according to manufacturers instructions. Briefly, the  
361 serum samples and the calibrators were incubated with <sup>125</sup>I-labeled estradiol, in the  
362 antibody-coated tubes provided by the manufacturer for 3 hours at room  
363 temperature. After decantation, the tubes were measured immediately. Tests were  
364 conducted in duplicate and results were expressed as mean  $\pm$  S.E.M (ng/ml).

365

#### 366 *Allogeneic stimulation.*

367 Spleens from pregnant NOD and BALB/c mice, and from C57Bl6J male were  
368 removed aseptically and single-cell suspensions were prepared.

369 NOD and BALB/c splenic cells (Responder cells) were resuspended in complete  
370 RPMI-1640 ( $1 \times 10^5$  cells/well). Male C57Bl6J splenocytes resuspended in complete  
371 RPMI-1640 ( $1 \times 10^5$  cells/well) were treated with mitomycin C (0.5 ng/ml, Sigma, St.  
372 Louis, MO) during 30 minutes at 37°C to inhibit paternal DNA synthesis (stimulator  
373 cells). The mixture of responder and stimulator cells was incubated in a U-shape  
374 microtitre plate (Corning) at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> in the  
375 presence or absence of progesterone ( $10^{-5}$  M, Sigma, St. Louis, MO)

376 After 72 hours, cells were pulsed with 1  $\mu$ Ci/ well of methyl-[<sup>3</sup>H]-thymidine [<sup>3</sup>H]TdR  
377 (NEN, Boston, MA) during the last 18h of cell culture, and then harvested on glass  
378 fiber filters using a Packard Filtermate cell harvester (Packard Instruments,

379 LaGrange, IL). Incorporated radioactivity was measured in a liquid scintillation  $\beta$ -  
380 counter (Packard Instruments). Tests were conducted in triplicate and results were  
381 expressed as mean cpm  $\pm$  S.E.M.

382

### 383 *Immunoblotting detection of Foxp3 and LIF*

384 Implantation sites explants were excised out, washed twice and incubated for 24 hs  
385 at 37°C in RPMI 1640 medium supplemented with 10% FCS (Life Technologies,  
386 Rockville, MD) in the presence or absence of VIP ( $10^{-7}$  M, Neosystem, France). After  
387 incubation, explants were homogenized at 4°C in 50 mM Tris-HCl buffer pH 7.5 with  
388 0.15 % Triton X-100 and protease inhibitors as previously reported for exocrine  
389 tissues and uterus (Rosignoli & Perez Leiros 2002; Roca *et al.* 2006). Once  
390 centrifuged at 5000xg 10 min at 4°C, supernatants were frozen at  $-80^{\circ}\text{C}$  until used  
391 and an aliquot of each sample was separated for protein determination. Extracts (50-  
392 100  $\mu\text{g}$  protein/lane), positive controls and molecular weight standards (Amersham  
393 Pharmacia Biotech Inc, NJ, USA) were subjected to 10% or 15% SDS-PAGE for  
394 Foxp3 (MW: 50 KD, Clone: FJK-16s, eBioscience, USA) and LIF (MW: 40 KD, Clone:  
395 9824.11, R&D, MN, USA) respectively, transferred to nitrocellulose membranes  
396 (Amersham Pharmacia Biotech Inc, NJ, USA) and revealed with ECL substrate  
397 reagent (Pierce Biotechnology, Woburn, MA, USA). The immunoreactive protein  
398 bands were analyzed with a Fotodyne Image Analyzer® (Fotodyne, Inc., Hartland,  
399 WI). Results were expressed as relative densitometric values by means of the Image  
400 Quant software relatives to  $\beta$ -actin expression.

401

### 402 *Flow Citometry analysis*

403 Regulatory T cells were identified using the *Mouse Regulatory T cell Staining Kit* (PE  
404 Foxp3 clone: FJK-16s, FITC CD4 clone: RM4-5, APC CD25 clone: PC61.5,  
405 eBioscience, USA) according to the manufacturer protocol. Implantation sites  
406 explants were excised out, washed twice and incubated for 24 h at 37°C in RPMI

407 1640 medium supplemented with 10% FCS (Life Technologies, Rockville, MD) in the  
408 presence or absence of VIP (10<sup>-7</sup> M, Neosystem, France). After incubation, explants  
409 were mechanically disrupted with a tissue homogenizer, and cellular suspension was  
410 centrifuged at 2000g 5 min at 4°C and pellets were resuspended. The prepared cells  
411 were stained for surface molecules CD4-FITC (0,125 µg/test) and CD25-APC (0,06  
412 µg/test ) in 100 µl staining buffer. The tests were incubated for 30 min 4°C, and then  
413 washed twice (2ml Staining buffer) centrifuged at 2000g 5 min 4°C and decanted.  
414 Pellet was resuspended with 1ml Fix/Perm Buffer and incubated for 30 m 4°C in the  
415 dark. After washing twice (2ml Perm buffer) and centrifuged at 2000g 5 min 4°C ,  
416 supernatants were decanted. Intracellular staining for Foxp3 was assed using Foxp3-  
417 PE antibody (0,5 µg/test ) in 100 µl Perm Buffer and incubated for 30 min 4°C in the  
418 dark. After washing twice (2ml Perm buffer) and centrifuged at 2000g 5 min 4°C ,  
419 supernatants were decanted and pellets resuspended in Flow Cytometry Staining  
420 Buffer for analysis. 100.000 events were acquired in a FACSCalibur cytometer® and  
421 results were analyzed using the WinMDI software®. Negative control samples were  
422 incubated in parallel with an irrelevant, isotype-matched antibody. Results for  
423 CD25<sup>+</sup>Foxp3<sup>+</sup> cells are inside the electronically gate performed by CD4 positive  
424 staining and on viable cell population, to avoid nonspecific uptake of Abs by dead  
425 cells.

426

#### 427 *RT-PCR for VIP and VPAC receptors detection*

428 Total RNA isolation and reverse transcription was performed using TRIZOL  
429 (Invitrogen, USA) and Ready-to-Go T primed First Strand Kit (Amersham Pharmacia  
430 Biotech Inc, NJ, USA) as previously described. (Rosignoli *et al.* 2004). The cDNA  
431 was then amplified using the specific primers for VIP, VPAC 1, VPAC 2 and GAPDH  
432 as internal control. Primers are described in Table 2 and PCR conditions are as  
433 follows: VIP, 95°C 10 min, 31 cycles of 96°C 45 s, 57°C 45 s, 72°C 1 min, and 72°C  
434 10 min, for VPAC 1/VPAC 2, 94°C 10 min, 35 cycles of 94°C 45 s, 55°C 45 s, 72°C

435 90 s and 72°C 10 min. Finally, PCR products and molecular markers were  
436 fractionated on 2% agarose gels and visualized by staining with ethidium bromide.  
437 Densitometry was performed and the results were expressed as arbitrary units  
438 normalized to GAPDH expression.

439 Real-Time RT-PCR assays for VIP mRNA expression were performed in the same  
440 conditions as RT-PCR. Briefly, for a final volume of 25  $\mu$ l, 2  $\mu$ l of cDNA, 0.20 mM  
441 dNTPs, 0.25  $\mu$ M specific primers, 3 mM MgCl<sub>2</sub>, 2 U Taq DNA polymerase, and  
442 1:30,000 dilution of Sybr Green were added to the reaction mix. Real-Time PCR  
443 reactions were performed in a DNA Engine Opticon (MJ Research Inc.). PCR  
444 products were quantified in the Opticon Software® and normalized to endogenous  
445 GAPDH. Each assay included a DNA minus control and a standard curve performed  
446 with serial dilutions of control cDNA. All samples were run in duplicate and the  
447 experiment was repeated three times with independently isolated RNA.

448

#### 449 *Statistics*

450 Statistical significance of differences was determined by the two-tailed t test for  
451 independent populations. When multiple comparisons were necessary, the Student-  
452 Newman-Keuls test was used after analysis of variance. Differences between groups  
453 were considered significant at  $P < 0.05$ .

454

#### 455 **Acknowledgements**

456 This work was supported by grants PICT 2165 from ANPCyT, PIP 5638 from  
457 CONICET and UBACyT X172 from University of Buenos Aires, Argentina. We are  
458 grateful to Dr Roberto Meiss from Academia Nacional de Medicina for histological  
459 studies presented in figure 2.

460

461

462

463 **References**

464

- 465 1. **Abraham GE, Swerdloff R, Tulchinaky D & Odell WD.** 1971  
466 Radioimmunoassay of plasma progesterone. *Journal of Clinical*  
467 *Endocrinology* **32**:619–624.
- 468 2. **Aisemberg J, Vercelli C, Billi S, Ribeiro ML, Ogando D, Meiss R, McCann**  
469 **SM, Rettori V & Franchi AM.** 2007 Nitric oxide mediates prostaglandins'  
470 deleterious effect on lipopolysaccharide-triggered murine fetal resorption.  
471 *Proceedings of the National Academy of Sciences* **104**:7534-7539.
- 472 3. **Aluvihare V, Kallikourdis M & Betz A** 2004 Regulatory T cells mediate  
473 maternal tolerance to the fetus. *Nature Immunology* **3**:266–271.
- 474 4. **Ancelin M, Buteau-Lozano H, Meduri G, Osborne-Pellegrin M, Sordello S,**  
475 **Plouet J & Perrot-Applanat M** 2002 A dynamic shift of VEGF isoforms with a  
476 transient and selective progesterone-induced expression of VEGF189  
477 regulates angiogenesis and vascular permeability in human uterus.  
478 *Proceedings of the National Academy of Sciences* **99**:6023– 6028.
- 479 5. **Anderson MS & Bluestone JA** 2005 The NOD mouse: a model of immune  
480 dysregulation. *Annual Review of Immunology* **23**:447-485.
- 481 6. **Burke S, Dong H, Hazan AD & Croy BA** 2007 Aberrant endometrial features  
482 of pregnancy in diabetic NOD mice. *Diabetes* **56**:1-8.
- 483 7. **Chaouat G, Menu E, Clark DA, Dy M, Minkowski M & Wegmann TG** 1990  
484 Control of fetal survival in CBA x DBA/2 mice by lymphokine therapy. *Journal*  
485 *of Reproduction and Fertility* **89**:447–458.
- 486 8. **Chiu L, Nishimura M, Ishi Y, Nieda M, Maeshima M, Takedani Y,**  
487 **Tadokoro K & Juji T** 1996 Enhancement of the expression of progesterone  
488 receptor on progesterone -treated lymphocytes after immunotherapy in  
489 unexplained recurrent spontaneous abortion. *American Journal Reproductive*  
490 *Immunology* **35**:552–557.

- 491 9. **Clark KE, Mills EG, Stys SJ & Seeds AE** 1981 Effects of vasoactive  
492 polypeptides on the uterine vasculature. *American Journal of Obstetrics and*  
493 *Gynecology* **139**:182–188.
- 494 10. **Cutolo M.** 2000 Sex hormone adjuvant therapy in rheumatoid arthritis.  
495 *Rheumatic Diseases Clinics of North America* **26**:881-895.
- 496 11. **Ekström J, Mansson B & Tobin G.** 1983 Vasoactive intestinal peptide  
497 evokes secretion of fluid and protein from rat salivary glands and the  
498 development of supersensitivity. *Acta Physiologica Scandinavica* **119**:169–  
499 175.
- 500 12. **Elson J & Jurkovic D** 2004 Biochemistry in diagnosis and management of  
501 abnormal early pregnancy. *Current Opinion in Obstetrics & Gynecology*  
502 **16**:339–344.
- 503 13. **Formby B, Schmid-Formby F, Jovanovic L & Peterson CM.** 1987 The  
504 offspring of the female diabetic "nonobese diabetic" (NOD) mouse are large  
505 for gestational age and have elevated pancreatic insulin content: a new  
506 animal model of human diabetic pregnancy. *Proceedings of the Society for*  
507 *Experimental Biology and Medicine.* **184**:291-294.
- 508 14. **Fraccaroli L, Alfieri J, Larocca L, Calafat M, Roca V, Lombardi E,**  
509 **Ramhorst R & Perez Leiros C.** 2009 VIP modulates the pro-inflammatory  
510 maternal response, inducing tolerance to trophoblast cells. *British Journal of*  
511 *Pharmacology.* **156**:116-26.
- 512 15. **Gonzalez Rey E & Delgado M.** 2007 Vasoactive intestinal peptide and  
513 regulatory T-cell induction: a new mechanism and therapeutic potencial for  
514 immune homeostasis. *Trends in Molecular Medicine* **13**:242-251.
- 515 16. **Gressens P, Hill JM, Paindaveine B, Gozes I, Fridkin M & Brenneman**  
516 **DE.** 1994 Severe microcephaly induced by blockade of vasoactive intestinal  
517 peptide function in the neuroepithelium of the mouse. *Journal of Clinical*  
518 *Investigation* **94**:2020-2027.

- 519 17. **Gressens P, Painsaveine B, Hill JM, Evrard P & Brenneman DE** 1998  
520 Vasoactive intestinal peptide shortens both G1 and S phases of neural cell  
521 cycle in whole postimplantation cultured mouse embryos. *European Journal*  
522 *of Neuroscience* **10**:1734–1742.
- 523 18. **Halonen M, Lohman IC, Stern DA, Spangenberg A, Anderson D, Mobley**  
524 **S, Ciano K, Peck M & Wright AL.** 2009 Th1/Th2 patterns and balance in  
525 cytokine production in the parents and infants of a large birth cohort. *Journal*  
526 *of Immunology* **182**:3285-3293.
- 527 19. **Hanzlikova J, Ulcova-Gallova Z, Malkusova I, Sefrna F & Panzner P.** 2009  
528 TH1-TH2 response and the atopy risk in patients with reproduction failure.  
529 *American Journal of Reproductive Immunology* **61**:213-220.
- 530 20. **Inoue Y, Kaku K, Kaneko T, Yanahara N & Kanno T** 1985 Vasoactive  
531 intestinal peptide binding to specific receptors on rat parotid acinar cells  
532 induces amylase secretion accompanied by cyclic adenosine 30-50-  
533 monophosphate. *Endocrinology* **116**:686–692.
- 534 21. **Jovanovic A, Jovanovic S, Tulic I & Grbovic L** 1998 Predominant role for  
535 nitric oxide in the relaxation induced by vasoactive intestinal polypeptide in  
536 human uterine artery. *Molecular Human Reproduction* **4**:71–76.
- 537 22. **Larocca L, Ramhorst R, Roca V, Calafat M, Aisemberg J, Franchi A &**  
538 **Pérez Leirós C.** 2008 Neuroimmune-endocrine interactions during early  
539 pregnancy in an autoimmune context: focus on macrophage activation.  
540 *Neuroimmunomodulation*. **15**:84-90.
- 541 23. **Leceta J, Gomariz RP, Martinez C, Carrión M, Arranz A & Juarranz Y.**  
542 2007 Vasoactive intestinal peptide regulates Th17 function in autoimmune  
543 inflammation. *Neuroimmunomodulation* **14**:134-138.
- 544 24. **Li W, Li B, Fan W, Geng L, Li X, Li L, Huang Z, Li S.** 2009 CTLA4lg gene  
545 transfer alleviates abortion in mice by expanding CD4+CD25+ regulatory T

- 546 cells and inducing indoleamine 2,3-dioxygenase. *Journal of Reproductive*  
547 *Immunology* **80**: 1–11.
- 548 25. **Lin Y, Xu L, Jin H, Zhong Y, Di J & Lin QD.** 2008 CXCL12 enhances  
549 exogenous CD4(+)CD25(+) T cell migration and prevents embryo loss in non-  
550 obese diabetic mice. *Fertility and Sterility* **91**:2687-2696.
- 551 26. **Marzioni D, Fiore G, Giordano A, Nabissi M, Florio P, Verdenelli F,**  
552 **Petraglia F & Castellucci M** 2005 Placental expression of Substance P and  
553 Vasoactive intestinal peptide: evidence for a local effect on hormone release.  
554 *Journal of Clinical Endocrinology & Metabolism* **90**:2378-2383.
- 555 27. **Metcalfe SM, Watson TJ, Shurey S, Adams E, & Green CJ.** 2005 Leukemia  
556 inhibitory factor is linked to regulatory transplantation tolerance.  
557 *Transplantation* **79**:726-730.
- 558 28. **Moriyama I & Sugawa T** 1972 Progesterone facilitates implantation of  
559 xenogeneic cultured cells in hamster uterus. *Nature: New Biology* **236**:150-  
560 152.
- 561 29. **Nelson JL & Ostensen M** 1997 Pregnancy and rheumatoid arthritis.  
562 *Rheumatic Diseases Clinics of North America* **23**:195-212.
- 563 30. **Ogando DG, Paz D, Cella M & Franchi AM.** 2003 The fundamental role of  
564 increased production of nitric oxide in lipopolysaccharide-induced embryonic  
565 resorption in mice. *Reproduction.* **125**:95-110
- 566 31. **Olsen NJ & Kovacs WJ** 2002 Hormones, pregnancy, and rheumatoid  
567 arthritis. *Journal of Gender-Specific Medicine.* **5**:28-37.
- 568 32. **Ottesen B, Ulrichsen H, Fahrenkrug J, Larsen JJ, Wagner G, Schierup L**  
569 **& Sondergaard F** 1982 Vasoactive intestinal polypeptide and the female  
570 genital tract: relationship to reproductive phase and delivery. *American*  
571 *Journal of Obstetrics and Gynecology* **143**:414–420.

- 572 33. **Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G & Romagnani S.** 1998  
573 Defective production of both, leukemia inhibitor factor and type 2 T-helper  
574 cytokines by decidual T cells in unexplained recurrent abortions. *Nature*  
575 *Medicine* **4**:1020–1024.
- 576 34. **Piccirillo CA, Tritt M, Sgouroudis E, Albanese A, Pyzik M & Hay V** 2005  
577 Control of type 1 autoimmune diabetes by naturally occurring CD4+CD25+  
578 regulatory T lymphocytes in neonatal NOD mice. *Annals New York Academy*  
579 *of Science* **1051**:72-87
- 580 35. **Pop SM, Wong CP, Culton DA, Clarke SH & Tisch R** 2005 Single cell  
581 analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+  
582 regulatory T cells during autoimmune diabetes. *Journal of Experimental*  
583 *Medicine* **201**:1333-1346.
- 584 36. **Raghupathy R,** 1997 Th1-type immunity is incompatible with successful  
585 pregnancy. *Immunology Today* **18**:478–482.
- 586 37. **Rangon CM, Dicou E, Goursaud S, Mounien L, Jégou S, Janet T, Muller**  
587 **JM, Lelièvre V & Gressens P** 2006 Mechanisms of VIP-induced  
588 neuroprotection against neonatal excitotoxicity. *Annals of the New York*  
589 *Academy of Science* **1070**:512-517.
- 590 38. **Roca V, Larocca L, Calafat M, Aisemberg J, Meiss R, Franchi A & Perez**  
591 **Leiros C** 2006 Reduced nitric oxide synthase and cyclo-oxygenase activity in  
592 the uterus of non-obese diabetic mice *Reproduction* **32**:931–938.
- 593 39. **Roca V, Rosignoli F, Calafat M, Pérez Leirós C** 2004 Lack of nitric oxide-  
594 mediated regulation of amylase secretion stimulated by VIP in parotid glands  
595 of NOD mice *International Immunopharmacology* **4**:1837-1844.
- 596 40. **Rosignoli F & Perez Leiros C** 2002 Nitric oxide synthase I and VIP activated  
597 signaling are affected in salivary glands of NOD mice. *Journal of*  
598 *Neuroimmunology* **130**:109–116.

- 599 41. **Rosignoli F, Roca V, Meiss R, Leceta J, Gomariz RP & Perez Leiros C**  
600 2005 Defective signalling in salivary glands precedes the autoimmune  
601 response in the non-obese diabetic mouse model of sialadenitis. *Clinical and*  
602 *Experimental Immunology* **142**:411–418.
- 603 42. **Rosignoli F, Roca V, Meiss R, Pregi N & Pérez Leirós C.** 2004 Inhibition of  
604 calcium-calmodulin kinase restores nitric oxide production and signaling in  
605 submandibular glands of a mouse model of salivary dysfunction. *British*  
606 *Journal Pharmacology* **143**:1058-1065.
- 607 43. **Rosignoli F, Torroba M, Juarranz Y, Garcia-Gomez M, Martinez C,**  
608 **Gomariz R, Perez Leiros C & Leceta J.** 2006 VIP and tolerance induction in  
609 autoimmunity. *Annals New York Academy of Science.* **1070**:525-530.
- 610 44. **Rugeles MT & Shearer GM** 2004 Alloantigen recognition in utero: dual  
611 advantage for the fetus? *Trends in Immunology* **25**: 348–352.
- 612 45. **Saito S, Shima T, Nakashima A, Shiozaki A, Ito M & Sasaki Y** 2007 What  
613 is the role of regulatory T cells in the success of implantation and early  
614 pregnancy? *Journal of Assisted Reproductive and Genetics* **24**:379–386.
- 615 46. **Siamopoulou-Mavridou A, Manoussakis MN, Mavridis AK &**  
616 **Moutsopoulos HM.** 1988 Outcome of pregnancy in patients with  
617 autoimmune rheumatic disease before the disease onset. *Annals of the*  
618 *Rheumatic Diseases* **47**:982:987.
- 619 47. **Spong CY, Lee SJ, McCune SK, Gibney G, Abebe DT, Alvero R,**  
620 **Brenneman DE & Hill JM.** 1999 Maternal regulation of embryonic growth:  
621 the role of vasoactive intestinal peptide. *Endocrinology* **140**:917-924.
- 622 48. **Szekeres-Bartho J.** 2002 Immunological relationship between the mother  
623 and the foetus. *International Review Immunology* **21**:471–495.
- 624 49. **Taiym S, Haghghat N & Al-Hashimi I** 2004 A comparison of the hormone  
625 levels in patients with Sjogren's syndrome and healthy controls. *Oral Surgery,*  
626 *Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics* **97**:579–583.

- 627 50. **Waldorf KM & Nelson JL** 2008 Autoimmune disease during pregnancy and  
628 the microchimerism legacy of pregnancy. *Immunological Investigations*  
629 **37**:631-644.
- 630 51. **Zenclussen AC, Gerlof K, Zenclussen ML, Ritschel S, Zambon Bertoja A,**  
631 **Fest S, Hontsu S, Ueha S, Matsushima K, Leber J & Volk HD** 2006  
632 Regulatory T cells induce a privileged tolerant microenvironment at the fetal-  
633 maternal interface *European Journal of Immunology* **36**:82–94.
- 634 52. **Zenclussen AC, Gerlof K, Zenclussen ML, Sollwedel A, Bertoja AZ, Ritter**  
635 **T, Kotsch K, Leber J & Volk HD.** 2005 Abnormal T-cell reactivity against  
636 paternal antigens in spontaneous abortion: adoptive transfer of pregnancy  
637 induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine  
638 abortion model. *American Journal of Pathology* **166**:811–822.
- 639
- 640

641 **Figure legends**

642 *Figure 1: Reduced litter size in NOD mice.*

643 NOD (A) and BALB/c (B) mice were singeneically mated during lifespan beginning at  
644 8 weeks and offspring was recorded as well as the mother's age at the time of  
645 parturition. Values represented are the mean  $\pm$  S.E.M. of 20 females. \*P<0.05 vs.  
646 NOD 1<sup>st</sup> litter.

647

648 *Figure 2: Increased resorption rate in prediabetic NOD mice*

649 A) Uteri from pregnant NOD mice were processed for histological studies and  
650 haematoxylin-eosin staining. Sections shown are representative of four other slices  
651 analyzed similarly, 250X. The arrows indicate: (a) mononuclear infiltrates, (b)  
652 hemorrhages, (c) detached cells. B) Resorption rate was calculated as the number of  
653 resorbed embryos over total embryos counted.

654

655 *Figure 3: Decreased progesterone serum levels.*

656 A) Freshly isolated serum from each animal, NOD mice with healthy implantation  
657 sites (NS, black bars), NOD mice showing sites with signs of resorption (RS, striped  
658 bars) and BALB/c mice (empty bars), were individually processed and progesterone  
659 and estradiol levels were determined by RIA as described in Materials and Methods.  
660 Values are the mean  $\pm$  S.E.M. of six separate animals. \*\*P<0.01 vs. BALB/c, a  
661 P<0.05 vs. NOD NS. B) Single-cell suspensions were prepared from pregnant NOD  
662 and BALB/c mice spleens and co-cultured with male C57Bl6J splenocytes, previously  
663 treated with mitomycin C (0.5 ng/ml) in the presence or absence of Progesterone ( $10^{-5}$   
664 M). After 72 hours, cells were pulsed with 1  $\mu$ Ci/well of methyl-[3H]-thymidine  
665 [3H]TdR and then harvested. Tests were conducted in triplicate and results were  
666 expressed as mean cpm  $\pm$  S.E.M. \*P<0.05 vs. basal.

667

668 *Figure 4: Decreased VIP mRNA levels in normal implantation sites of NOD mice*

669 A) VIP mRNA expression was evaluated by RT-PCR from normal implantation sites  
670 (NS, black bars) of NOD mice, NOD sites with signs of resorption (RS, grey bars)  
671 and BALB/c mice normal sites (empty bars) as described in Materials and Methods.  
672 Agarose gels shown are representative of three others. Values indicate the mean  
673 intensity relative to GAPDH of each band in arbitrary units (AU) and represent the  
674 mean  $\pm$  S.E.M. for three separate experiments. \*P<0.05 vs. BALB/c. a P<0.05 vs.  
675 NOD NS.

676 B) VIP mRNA expression was quantified by real time RT-PCR from NOD mice  
677 normal sites (NS, black bars), NOD mice sites with signs of resorption (RS, grey  
678 bars) and BALB/c mice normal sites (empty bars) as described in Materials and  
679 Methods. Values indicate the mean intensity relative to GAPDH of each test in  
680 arbitrary units (AU) and represent the mean  $\pm$  S.E.M. for three separate experiments.  
681 \*P<0.05 vs BALB/c. a P<0.05 vs NOD NS

682 C) VPAC<sub>1</sub> and VPAC<sub>2</sub> mRNA expression was evaluated by RT-PCR from normal  
683 implantation sites of NOD mice (black bars), and BALB/c mice (empty bars) as  
684 described in Materials and Methods. Agarose gels shown are representative of three  
685 others. Values indicate the mean intensity relative to GAPDH of each band in  
686 arbitrary units (AU) and represent the mean  $\pm$  S.E.M. for three separate experiments.  
687

688 *Figure 5: Effect of VIP on pro-implantatory factors.*

689 The effect of VIP on the expression of Foxp3 and LIF in normal implantation sites of  
690 NOD and BALB/c mice was assessed by immunoblotting, after a 24hs culture in  
691 presence or absence of VIP ( $10^{-7}$ M) as described in Materials and Methods. A) Blots  
692 shown are representative of five others. Bars on the right side indicate the mean  
693 intensity relative to  $\beta$ -actin expression of each band in arbitrary units and represent  
694 the mean  $\pm$  S.E.M. of five blots. B: Basal values, VIP-treated (gray bars), \*P<0.05 vs.  
695 basal.

696 B) VIP effect on Tregs frequency was assessed in viable implantation sites from  
697 NOD and BALB/c mice by FACS analysis as described in Materials and Methods.  
698 Dot plots presented are representative of two other experiments run similarly.

699


700 *Table 1: Glucose levels in 16 weeks old pregnant NOD mice*

701 Freshly isolated serum from each pregnant animal either NOD or BALB/c was  
702 individually processed and glucose levels were determined as described in Materials  
703 and Methods. Values are the mean  $\pm$  S.E.M. of six separate determinations.


704

705 *Table 2: Primer sequences*

706




170x91mm (400 x 400 DPI)




**B**

Resorption rate: 60 / 187 ( 32% )  
(Resorbed embryos/  
total embryos)



180x134mm (400 x 400 DPI)



120x109mm (400 x 400 DPI)



120x136mm (400 x 400 DPI)



158x137mm (400 x 400 DPI)

Table 1: Glucose serum levels in pregnant 16 weeks old NOD mice

	NOD 1 <sup>st</sup> gestation	NOD 3 <sup>rd</sup> gestation	BALB/c
Glucose (g/l)	0,8 ±0,2	0,75±0,1	1,0±0,1

Table 2: primers sequences

VIP	sense: 5'TTC ACC AGC GAT TAC AGC AG 3'	antisense: 5'TCA CAG CCA TTT GCT TTC TG 3'
VPAC1	sense: 5'GTG AAG ACC GGC TAC ACC AT 3'	antisense: 5'TGA AGA GGG CCA TAT CCT TG 3'
VPAC2	sense: 5' CCA AGT CCA CAC TGC TGC TA 3'	antisense: 5' CCT CGC CAT CTT CTT TTC AG 3'
GAPDH	sense: 5'TGA TGA CAT CAA GAA GGT GGT GAA G 3'	antisense: 5'TCC TTG GAG GCC ATG TAG GCC AT 3'